3
Jun
2021
Amgen’s KRAS Triumph, Eric Lander in the Saddle, and EQRx Takes Aim at PD-L1
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
3
Jun
2021
Stablix, Seeking to Stabilize Instead of Degrade Proteins, Raises $63M
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.